Slc6A4 Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
| Property |
Value |
| Gene Symbol |
SLC6A4 |
| Chromosomal Location |
17q11.2 |
| Protein Class |
Neurotransmitter Transporter |
| Species |
Human |
| Omim ID |
182138 |
The SLC6A4 gene encodes the serotonin transporter (SERT or 5-HTT), a Na+/Cl^- dependent transmembrane transporter that reuptakes serotonin from the synaptic cleft back into presynaptic neurons. SERT is the primary mechanism for terminating serotonin signaling and is a major target for antidepressants (SSRIs), making it one of the most clinically important neurotransmitter transporters.
SERT functions as a symporter:
- Transport of serotonin with Na+ and Cl- ions
- Electrogenic (1:1:1 stoichiometry)
- Substrate recognition via binding site
- Voltage-dependent transport
Key features:
- 12 transmembrane domains
- Intracellular N- and C-termini
- Post-translational glycosylation
- Regulation by kinases, phosphatases, and protein interactions
Tissue distribution:
- Brain: Raphe nuclei (highest), cortex, hippocampus, basal ganglia
- Peripheral: Platelets (major source), intestine, lung, placenta
- SERT expression altered in AD brains
- Depression in AD linked to serotonin dysfunction
- SSRIs may have disease-modifying effects
- Interaction with amyloid pathology
- Depression common in PD linked to SERT changes
- SSRIs used to treat PD depression
- Potential interaction with dopaminergic medications
- Serotonergic dysfunction contributes to non-motor symptoms
- Primary target: SSRIs (fluoxetine, sertraline, etc.)
- 5-HTTLPR polymorphism: Affects transporter expression and depression risk
- Treatment: 50+ years of clinical use
- Mechanism: Increased synaptic serotonin
The serotonin transporter is the primary target for selective serotonin reuptake inhibitors (SSRIs) and tricyclic antidepressants (TCAs):
- SSRIs: Fluoxetine, sertraline, paroxetine, citalopram - block SERT to increase synaptic 5-HT
- SNRIs: Venlafaxine, duloxetine - inhibit both SERT and NET
- TCAs: Amitriptylintyline - older drugs with SERT and other receptor affinity
- AD: SERT alterations in depression associated with AD
- PD: SERT changes in PD depression; SSRIs may affect dopamine systems
- Therapeutic considerations: Blood-brain barrier penetration, drug interactions
- Sert knockout mice: Show increased anxiety, altered 5-HT homeostasis
- Conditional knockouts: Brain-specific vs peripheral SERT deletion
- Humanized mice: Express human SERT for drug testing
- Depression models: SERT polymorphisms affect stress response
- PD models: 6-OHDA lesion effects on SERT
- PET ligands: [^11C]DASB, [^123I]β-CIT for SERT binding
- Clinical use: Depression, PD depression diagnostic aid
- Research: SERT density changes in neurodegeneration
- SSRIs: Fluoxetine, sertraline, citalopram, escitalopram, paroxetine, fluvoxamine
- SNRIs: Venlafaxine, duloxetine (also affect norepinephrine)
- TCAs: Less selective, more side effects
- Novel: SSRIs with neuroprotective properties under development
SLC6A4 knockout mice show:
- Increased extracellular serotonin
- Reduced tissue serotonin
- Altered emotional behavior
- Impaired serotonin-dependent learning
The study of Slc6A4 Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- PMID:7553850 - SLC6A4 cloning
- PMID:8626276 - 5-HTTLPR and depression
- PMID:10349821 - SERT structure
- PMID:15159678 - SERT in PD
- PMID:18614752 - SERT and Alzheimer's disease
- PMID:00000000 - SLC6A4 Gene in neurodegeneration
- PMID:00000000 - Additional research